Jervaughn Hunter, the paper’s first author, left, with his Ph.D. adviser, UC San Diego bioengineering professor Karen Christman, in the lab. They took part in the research establishing a hydrogel as a potential mitigation for right ventricle damage. [Image courtesy of UCSD]
Researchers say an injectable hydrogel could mitigate damage to the right ventricle of the heart with chronic pressure overload.The research came out of the University of California San Diego, Georgia Institute of Technology and Emory University. Investigators published their work in Journals of the American College of Cardiology: Basic to Translational Science.
For this study, they used rodents, but a 2019 FDA-approved Phase 1 trial demonstrated the hydrogel’s safety in humans who suffered a heart attack. As a result of the new preclinical study, the FDA approved an investigational new drug application (NDA). The teams …